Open for inclusion

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)

Cancer type: Lung cancer

Phase: II

Principal Investigator: Helland Åslaug

Country: NO

Keywords: Norway, Oslo, lung, uv1, mesoteliom, nivolumab, ibilimumab

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04300244